Advertisement

 

 

Predictors of weight loss in early treated Parkinson’s disease from the NET-PD LS-1 cohort.

Predictors of weight loss in early treated Parkinson’s disease from the NET-PD LS-1 cohort.
Author Information (click to view)

Wills AM, Li R, Pérez A, Ren X, Boyd J, ,


Wills AM, Li R, Pérez A, Ren X, Boyd J, , (click to view)

Wills AM, Li R, Pérez A, Ren X, Boyd J, ,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Journal of neurology 2017 07 15() doi 10.1007/s00415-017-8562-4
Abstract

Weight loss is a common symptom of Parkinson’s disease and is associated with impaired quality of life. Predictors of weight loss have not been studied in large clinical cohorts. We previously observed an association between change in body mass index and change in Unified Parkinson’s Disease Rating Scale (UPDRS) motor and total scores. In this study, we performed a secondary analysis of longitudinal data (1-6 years) from 1619 participants in the NINDS Exploratory Trials in PD Long-term Study-1 (NET-PD LS1) to explore predictors of weight loss in a large prospective clinical trial cohort of early treated Parkinson’s disease. The NET-PD LS1 study was a double-blind randomized placebo controlled clinical trial of creatine monohydrate 10 gm/day in early treated PD (within 5 years of diagnosis and within 2 years of starting dopaminergic medications). Linear mixed models were used to estimate the effect of baseline clinical covariates on weight change over time. On average, participants lost only 0.6 kg per year. Higher age, baseline weight, female gender, higher baseline UPDRS scores, greater postural instability, difficulty eating and drinking, lower cognitive scores and baseline levodopa use (compared to dopamine agonists) were all associated with weight loss. Surprisingly baseline difficulty swallowing, dyskinesia, depression, intestinal hypomotility (constipation) and self-reported nausea/vomiting/anorexia were not significantly associated with weight loss in this cohort of early treated Parkinson’s disease patients. On average, participants with Parkinson’s disease experience little weight loss during the first 1-6 years after starting dopaminergic replacement therapy, however levodopa use and postural instability were both predictors of early weight loss. Trial Registration clinicaltrials.gov identifier# NCT00449865.

Submit a Comment

Your email address will not be published. Required fields are marked *

four × four =

[ HIDE/SHOW ]